U.S. markets open in 10 minutes

ADC Therapeutics SA (ADCT)

NYSE - NYSE Delayed Price. Currency in USD
5.05+0.33 (+6.99%)
At close: 04:00PM EST
5.19 +0.14 (+2.77%)
Pre-Market: 09:05AM EST

ADC Therapeutics SA

Route de la Corniche 3B
Epalinges 1066
41 21 653 02 00

Full Time Employees312

Key Executives

NameTitlePayExercisedYear Born
Dr. Christopher J. Martin DPHIL, Ph.D.Co-Founder & Non-Exec. Director1.46MN/A1959
Dr. Patrick van Berkel Ph.D.Chief Scientific OfficerN/AN/A1968
Ms. Susan RomanusChief Compliance & Quality OfficerN/AN/A1965
Ms. Kimberly PopeSr. VP & Chief People OfficerN/AN/A1966
Dr. Ameet Mallik M.B.A., M.S.CEO & DirectorN/AN/A1972
Mr. Jose I. Carmona M.B.A.Chief Financial OfficerN/AN/A1972
Dr. Michael Mulkerrin Ph.D.Chief Technical Operations OfficerN/AN/AN/A
Amanda HamiltonInvestor Relations OfficerN/AN/AN/A
Mr. Peter J. Graham Esq.Chief Legal OfficerN/AN/A1967
Mr. David M. GilmanChief Bus. & Strategy OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Corporate Governance

ADC Therapeutics SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.